Rchr
J-GLOBAL ID:200901048593517676   Update date: Sep. 29, 2024

KIMINORI KIMURA

キムラ キミノリ | KIMINORI KIMURA
Affiliation and department:
Research field  (2): Tumor diagnostics and therapeutics ,  Gastroenterology
Research keywords  (3): 肝がん ,  肝硬変 ,  肝線維化
Research theme for competitive and other funds  (8):
  • 2022 - 2025 肝細胞がんに対する新規免疫チェックポイント阻害剤併用療法の開発
  • 2018 - 2021 Elucidation of the mechanism of liver fibrosis by Wnt-b-catenin pathway
  • 2015 - 2018 Development of new anti-fibrotic therapeutic drug for targeting Wnt signal
  • 2013 - 2016 C型肝炎ウイルスに起因する肝硬変に対する抗線維化治療薬の開発に関する研究
  • 2012 - 2014 ウイルス肝炎持続感染モデルを用いた革新的治療ワクチンの開発
Show all
Papers (59):
  • Kenzaburo Yamaji, Sadahiro Iwabuchi, Yuko Tokunaga, Shinichi Hashimoto, Daisuke Yamane, Sakiko Toyama, Risa Kono, Bouchra Kitab, Kyoko Tsukiyama-Kohara, Yosuke Osawa, et al. Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023. 166. 115379-115379
  • Yui Mukade, Sayaka Kobayashi, Yoshimi Nishijima, Kiminori Kimura, Akira Watanabe, Hayato Ikota, Ken Shirabe, Hideaki Yokoo, Masanao Saio. Phosphotungstic Acid-treated Picrosirius Red Staining Improves Whole-slide Quantitative Analysis of Collagen in Histological Specimens. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2022. 221554221141140-221554221141140
  • Masamichi Kimura, Eiichi Ogawa, Kenichi Harada, Jun Imamura, Masanao Saio, Yoshihiro Ikura, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Ichiro Ieiri, et al. Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study. BMJ open gastroenterology. 2022. 9. 1
  • Masamichi Kimura, Koji Nishikawa, Yosuke Osawa, Jun Imamura, Kenzaburo Yamaji, Kenichi Harada, Hiroshi Yatsuhashi, Kazumoto Murata, Kouichi Miura, Atsushi Tanaka, et al. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease. Hepatology communications. 2022. 6. 10. 2732-2747
  • Kiminori Kimura, Tatsuya Kanto, Shinji Shimoda, Kenichi Harada, Masamichi Kimura, Koji Nishikawa, Jun Imamura, Eiichi Ogawa, Masanao Saio, Yoshihiro Ikura, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. eBioMedicine. 2022. 80. 104069-104069
more...
MISC (51):
  • Masamichi Kimura, Koji Nishikawa, Jun Imamura, Keni-chi Harada, Masashi Mizokami, Kiminori Kimura. Safety, tolerability, and anti-fibrotic effect of PRI-724, a CBP/beta-catenin inhibitor, in patients with hepatitis C virus cirrhosis: A single-center, open-label, dose escalation phase 1 trial. HEPATOLOGY. 2017. 66. 6. 1262A-1262A
  • Yohei Mano, Sachiyo Yoshio, Hirotaka Shoji, Masaya Sugiyama, Hiroyoshi Doi, Toru Okamoto, Yosuke Osawa, Kiminori Kimura, Tomoharu Yoshizumi, Ken Shirabe, et al. Critical roles of bone morphogenetic protein 4 in cirrhotic and cancer-associated fibroblasts that regulates cellar senescence and cancer-supportive phenotype in the human liver. HEPATOLOGY. 2016. 64. 86A-86A
  • Kiminori Kimura, Kenichi Harada, Takuji Okusaka, Kazuaki Inoue, Shinji Shimoda, Tatsuya Kanto, Masashi Mizokami. Single-Centre, Dose Escalation, Open-Label Phase 1 Trial of the experimental anti-fibrotic small molecule PRI-724 in Patients with Hepatitis C virus related Cirrhosis. HEPATOLOGY. 2016. 64. 41A-42A
  • 大保木啓介, 小川美奈, 東瞳, 平間千津子, 貞任大地, 重本和宏, 藤田泰典, 中村清吾, 桑山隆志, 垂野香苗, et al. 次世代シークエンスによるがん組織中のウイルスの探索. 日本分子生物学会年会プログラム・要旨集(Web). 2016. 39th. ROMBUNNO.1P-0840 (WEB ONLY)
  • Hirotaka Shoji, Sachiyo Yoshio, Yohei Mano, Masaya Sugiyama, Yoshihiko Aoki, Norio Itokawa, Masanori Atsukawa, Yosuke Osawa, Kiminori Kimura, Akinobu Taketomi, et al. Pro-angiogenic Tie2-expressing monocytes/TEMs as a biomarker of the response to sorafenib in patients with advanced hepatocellular carcinoma. HEPATOLOGY. 2015. 62. 449A-449A
more...
Education (2):
  • 1995 - 1999 岐阜大学大学院医学研究科
  • - 1993 Gifu University School of Medicine
Work history (7):
  • 2014/04 - 現在 東京都立駒込病院 肝臓内科 部長
  • 2008/07 - 2014/03 東京都立駒込病院 肝臓内科 医長
  • 2007/04 - 2008/06 東京大学附属病院 免疫細胞治療学 助教
  • 2005/04 - 2007/03 Gifu University
  • 2002/07 - 2005/03 岐阜大学付属病院 第一内科
Show all
Awards (4):
  • 2010 - 日本肝臓学会研究奨励賞
  • 2010 - 日本消化器病学会研究奨励賞
  • 2007 - 東海学術研究奨励賞
  • 2005 - 岐阜医学協議会研究奨励賞
Association Membership(s) (5):
アメリカ肝臓学会 ,  日本癌学会 ,  日本消化器病学会 (評議員) ,  日本肝臓学会(評議員) ,  日本内科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page